Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

Joe Gebbia, a confidant of the technology billionaire and a Tesla director, is also a leader of the federal cost-cutting team ...

Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard ...

Lars Fruergaard’s surprise departure from Novo Nordisk is not sitting particularly well with analysts. Lukas Leu, a portfolio manager at Bellevue Asset Management, for example, ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Lars Fruergaard Jorgensen had led Denmark’s Novo since 2017. Ritzau Scanpix/AFP via Getty Images. He told Reuters that discussions to replace Jorgensen had taken place over the past few weeks.

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, to step down as company seeks a turnaround. Company found success with Wegovy and Ozempic, but share price has fallen by half in past year.

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership.

It’s the end of an era at Novo as longtime CEO Lars Fruergaard Jørgensen—who shepherded the company through its GLP-1 growth boom—heads for the exit.